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We screened a panel of mouse and human mono-
clonal antibodies (MAbs) against chikungunya virus
and identified several with inhibitory activity against
multiple alphaviruses. Passive transfer of broadly
neutralizing MAbs protected mice against infection
by chikungunya, Mayaro, and O’nyong’nyong alpha-
viruses. Using alanine-scanning mutagenesis, loss-
of-function recombinant proteins and viruses, and
multiple functional assays, we determined that
broadly neutralizing MAbs block multiple steps in
the viral lifecycle, including entry and egress, and
bind to a conserved epitope on the B domain of the
E2 glycoprotein. A 16 A˚ resolution cryo-electron mi-
croscopy structure of a Fab fragment bound to
CHIKV E2 B domain provided an explanation for its
neutralizing activity. Binding to the B domain was
associated with repositioning of the A domain of E2
that enabled cross-linking of neighboring spikes.
Our results suggest that B domain antigenic determi-
nants could be targeted for vaccine or antibody ther-
apeutic development against multiple alphaviruses
of global concern.
INTRODUCTION
Alphaviruses are arthropod-transmitted single-stranded posi-
tive-sense-enveloped viruses of the Togaviridae family and
cause disease worldwide. The two surface glycoproteins on
the mature virion, E2 and E1, facilitate binding and entry through
receptor-mediated endocytosis and low-pH-mediated fusion
within endosomes (Lescar et al., 2001; Smith et al., 1995). Alpha-
virus virions have T = 4 quasi-icosahedral symmetry, with 240Ccopies of the E2-E1 heterodimer assembling into 80 trimeric
spikes on the viral surface (Cheng et al., 1995). Twenty of these
spikes (‘‘i3’’) are coincident with the icosahedral 3-fold axes, and
60 are in general positions at quasi 3-fold axes (‘‘q3’’). X-ray crys-
tallographic structures have been determined of the E1 glyco-
protein, the p62-E1 precursor, the E2-E1 heterodimer, and the
(E1-E2)3 trimer (Lescar et al., 2001; Li et al., 2010; Roussel
et al., 2006; Voss et al., 2010). The mature E2 protein contains
three domains: an A domain, which is located centrally on the
surface of the spike and possesses the putative receptor binding
site; the B domain, located on the distal end of the spike,
covering the fusion loop on E1; and the C domain, at the proximal
end of the spike. The E1 protein is a type II membrane fusion pro-
tein containing three b-barrel domains. Domain I is located
spatially between domains II and III, with the fusion peptide lying
at the distal end of domain II (Lescar et al., 2001; Voss et al.,
2010). The E1 protein lies at the base of the trimeric spike with
E2 positioned on top of it.
Chikungunya virus (CHIKV) is transmitted to humans by Aedes
species of mosquitoes and causes a debilitating infection char-
acterized by fever, rash, myositis, and arthritis, with joint disease
lasting in some individuals for several years (Schilte et al., 2013).
CHIKV historically caused outbreaks in Africa and Asia. In 2013,
transmission of CHIKV occurred in theWestern Hemisphere, and
in just 18months, CHIKV has causedmore than 1.4million cases
in the Americas in more than 40 countries, including locally ac-
quired infections in Florida (Kendrick et al., 2014). In comparison,
other arthritogenic alphaviruses (e.g., Ross River [RRV], Semliki
Forest [SFV], Mayaro [MAYV], and Sindbis [SINV] viruses) circu-
late with more limited global distribution, with outbreaks in Oce-
ania, Africa, and South America.
Although currently there are no available licensed vaccines
or therapies for CHIKV or any other alphavirus, studies have
demonstrated the importance of antibody-mediated protection
(Kam et al., 2012; Lum et al., 2013). Passive transfer of g-globulin
purified from the plasma of CHIKV-immune patients to miceell 163, 1095–1107, November 19, 2015 ª2015 Elsevier Inc. 1095
Table 1. Cross-Reactivity of Mouse and Human MAbs against Different Alphavirusesa
Antibody CHIKV ONNV RRV MAYV SFV UNAV BEBV GETV MIDV BFV
% E2 Identity 83.0 56.6 56.2 57.6 54.5 56.4 54.3 51.3 41.8
CHK-48 ++ ++ ++ ++ ++ ++
CHK-65 ++ ++ ++ ++ ++
CHK-77 ++ ++ ++ ++ ++ ++ ++
CHK-88 ++ ++ ++ ++ ++ ++
CHK-96 ++ ++ ++ ++
CHK-98 ++ ++ ++
CHK-105 ++ ++ ++
CHK-124 ++ ++ ++ ++ ++ ++
CHK-187 ++ ++ ++ ++ ++ ++ ++ ++
CHK-265 ++ ++ ++ ++ ++ ++ ++ ++
1I9 ++ ++ ++ ++ ++ ++ ++
2C2 ++ ++ ++ ++ ++
2D12 ++ ++ ++ ++ ++ ++ ++ ++
2H1 ++ ++ ++
4B8 ++ ++ ++
5F10 ++ ++ ++ ++
8I4 ++ ++ ++ ++ ++ ++
9D14 ++ ++ ++ ++ ++ ++ ++ ++ ++
CHIKV, Chikungunya virus; ONNV, O’nyong’nyong virus; RRV, Ross River virus; SFV, Semliki Forest virus; MAYV, Mayaro virus; UNAV, Una virus;
GETV, Getah virus; BEBV, Bebaru virus; MIDV, Middelburg virus; and BFV, Barmah Forest virus. See also Figures S1 and S2.
a‘‘++’’ denotes positive staining, and an absence of a symbol denotes negative staining by flow cytometry on infected cells.prevented mortality following a lethal CHIKV infection (Couderc
et al., 2009). Analogously, monoclonal antibodies (MAbs)
neutralize CHIKV infection in vitro and protect against disease
in mice and non-human primates (Fong et al., 2014; Fric
et al., 2013; Goh et al., 2013; Pal et al., 2013, 2014; Smith
et al., 2015).
One goal of vaccine and therapeutic efforts against viruses is
the development of broadly neutralizing antibodies that inhibit
most strains within a genetically diverse virus family. Broadly
neutralizing MAbs have been described for human immunodefi-
ciency (HIV), influenza A (IAV), dengue (DENV), and hepatitis C
(HCV) viruses (reviewed in Corti and Lanzavecchia, 2013).
Although broadly neutralizing MAbs against alphaviruses have
not been described, polyclonal antibodies (induced by a CHIKV
vaccine candidate) protected against O’nyong’nyong virus
(ONNV) infection (Partidos et al., 2012) and convalescent serum
from RRV-infected mice protected against CHIKV pathogenesis
(Gardner et al., 2010). Earlier reports described cross-protection
between different alphaviruses using hyperimmune serum (Wust
et al., 1987). These studies suggest that conserved epitopes
exist across different alphaviruses that are recognized by pro-
tective antibodies.
We screened a panel of murine and human MAbs against
CHIKV (Pal et al., 2013; Smith et al., 2015) for neutralization of
different alphaviruses. We identified ten MAbs that neutralized
at least two different alphaviruses and showed that these
MAbs blocked multiple steps in the viral lifecycle, including entry
and egress. Two broadly neutralizing MAbs, CHK-187 and CHK-
265, protected in vivo against CHIKV, ONNV, and MAYV. Ge-1096 Cell 163, 1095–1107, November 19, 2015 ª2015 Elsevier Inc.netic analyses established that broadly neutralizing anti-alphavi-
rus MAbs recognized an epitope centered on the B domain of
the E2 protein. Cryo-electron microscopic studies showed
that binding of CHK-265 to the B domain on CHIKV was associ-
ated with repositioning of the A domain away from its native
position in the E2-E1 heterodimer, which facilitated interaction
with an edge of the A domain and cross-linking of adjacent E2
protein spikes. Overall, these studies describe a class of broadly
neutralizing antibodies with protective activity that inhibit entry
and egress of distantly related viruses within the alphavirus
genus.
RESULTS
Anti-CHIKV MAbs Cross-Neutralize Related
Arthritogenic Alphaviruses
Previously, we identified a panel of neutralizing mouse and hu-
man MAbs that inhibited infection of multiple CHIKV strains
(Pal et al., 2013; Smith et al., 2015). As a first step toward evalu-
atingwhetherMAbs against CHIKV had inhibitory activity against
distinct alphaviruses with envelope protein amino acid identities
ranging from 42.2% to 86.3% (Figure S1), we assessed immuno-
reactivity by flow cytometry (Figure S2). From the panel of 60
neutralizing anti-CHIKV MAbs, ten mouse MAbs and eight
human MAbs bound to three or more different viruses (Table 1).
However, these cross-reactive MAbs did not bind to cells in-
fected with Venezuelan equine encephalitis virus (data not
shown), which is more divergent (45.3% amino acid identity
with CHIKV).
Figure 1. Murine and Human Anti-CHIKV MAbs Neutralize Infection of MAYV, RRV, ONNV, and SFV
(A–G) MAbs were incubated with 102 FFU of (A, F, G) CHIKV, (B, F, G) Mayaro, (C, F, G) Ross River, (D) O’nyong’nyong, or (E, F, G) Semliki Forest viruses for 1 hr at
37C followed by addition of MAb-virus mixture to Vero cells for 18 hr. Virally infected foci were stained and counted. Wells containing MAb were compared to
wells containing no MAb to determine the relative infection. DENV1-E98 was included as an isotype control MAb.
(H). EC50 values were determined by non-linear regression and are shown as ng/ml (95%CI). Each graph represents themean and standard deviation (SD) from at
least two independent experiments.
See also Figure S1.We evaluated the neutralization potential of the cross-reactive
MAbs against alphaviruses that are closely (ONNV) or distantly
(MAYV, RRV, and SFV) related to CHIKV. As anticipated, each
of the MAbs neutralized CHIKV infection efficiently (Figures 1A
and 1H), as reported previously (Pal et al., 2013; Smith et al.,
2015). Of the ten cross-reactive mouse MAbs tested, eight
neutralized MAYV, seven neutralized SFV, six neutralized
ONNV, and three neutralized RRV (Figures 1B-1E and 1H). Unex-
pectedly, cross-neutralization of MAYV was greater than ONNV
even though the latter virus is more closely related to CHIKV (Fig-
ure S1). Three MAbs (CHK-48, CHK-187, and CHK-265) neutral-
ized all alphaviruses tested, with CHK-187 and CHK-265
showing the greatest potency (Figure 1H). Of the eight cross-Creactive human MAbs tested, only two (2H1 and 8I4) cross-
neutralized MAYV, RRV, and/or SFV (Figure 1F and 1G). The
sequences of humanMAb 8I4 antibody variable geneswere con-
ventional; it used the most commonly expressed VH gene (VH3-
23), had a high level of identity with germline sequences (99%
[278 of 282 nucleotides] with VH3-23*04 and 90% [45 of 50 nu-
cleotides] with JH5*02), and had an HCDR3 length of 18.
Broadly Neutralizing MAbs Protect In Vivo against
Multiple Alphaviruses
We assessed the efficacy of CHK-187 and CHK-265 in vivo
against CHIKV using an arthritis model in wild-type (WT) mice
(Morrison et al., 2011). A single 100 mg dose of CHK-187,ell 163, 1095–1107, November 19, 2015 ª2015 Elsevier Inc. 1097
CHK-265, or an isotype control MAb was administered 1 day
prior to infection with 103 FFU of CHIKV in the footpad. Treat-
ment with CHK-187 or CHK-265 reduced ankle joint swelling
to nearly baseline at 3 days after infection when compared to
the isotype control MAb (Figure 2A). CHK-187 diminished the
CHIKV burden in the ipsilateral ankle and prevented virus
dissemination, whereas CHK-265 reduced spread to the contra-
lateral ankle joint (Figure 2B).
Since the greatest cross-neutralization by CHK-265 or CHK-
187 was against MAYV, we assessed the protective efficacy of
these two MAbs in vivo against MAYV infection. To do this, we
developed a new arthritis model of MAYV inWTmice. After inoc-
ulation with 103 FFU of MAYV, mice developed joint swelling,
similar to that observed after CHIKV infection. Using this model,
100 mg of CHK-265, CHK-187, or an isotype control MAb was
administered 1 day prior to infection, and ankle size was
measured. Additionally, serum, spleen, quadriceps muscle,
and ankles were collected on day 3 after infection. Treatment
with CHK-265 or CHK-187 reduced joint swelling compared to
isotype control MAb-treated animals (Figure 2C). The reduced
disease correlated with decreased viral burden, as CHK-187
diminished viral load in the spleen, muscle, and contralateral
ankle (Figure 2D). Remarkably, CHK-265 completely protected
against MAYV infection, with no detectable virus at the site of
inoculation or in any other tissue analyzed.
As an additional test, we evaluated the efficacy of CHK-265
and CHK-187 against ONNV infection. Since ONNV does not
replicate extensively in WT mice (Seymour et al., 2013), we
developed an arthritis model in Ifnar/ immunodeficient mice.
After infection with ONNV, Ifnar/ mice developed ankle
swelling and hind limb weakness, with variable rates of recovery.
All mice receiving the isotype control MAb developed joint
swelling and limb weakness. In contrast, mice receiving CHK-
187 or CHK-265 showed minimal clinical disease (Figure 2E),
reduced joint swelling from day 5 through day 14 after infection
(Figure 2F), and greater weight gain (Figure 2G). To confirm
that reduced disease was linked to decreased ONNV infection,
we measured viral burden in the spleen, quadriceps muscles,
and ankles 5 days after infection. CHK-187 reduced ONNV
infection in the ipsilateral foot as well as at distant sites
compared to isotype control MAb-treated animals (Figure 2H).
CHK-265 limited ONNV spread to the contralateral joint and
muscle. Thus, at least two broadly neutralizingMAbs can protect
against infection and disease caused by multiple arthritogenic
alphaviruses.
Cross-Protective MAbs Map to the B Domain of the E2
Glycoprotein
The binding sites of broadly neutralizing mouse and human
MAbs were mapped by alanine-scanning mutagenesis and
mammalian cell display (Davidson and Doranz, 2014) of the E2,
6K, and E1 proteins (Figure S3). All cross-neutralizing MAbs
bound primarily to sites within the B domain of the E2 protein
(Figures 3A and 3B). Eight amino acids (Q184, S185, I190,
V197, Y199, G209, L210, I217) emerged as critical for binding
(Figure 3A and 3B). These residues are highly conserved across
CHIKV E2 proteins, as determined by alignment of 415 genome
sequences (http://www.viprbrc.org) (Figure 3C). Variation was1098 Cell 163, 1095–1107, November 19, 2015 ª2015 Elsevier Inc.detected only at amino acid position 210 on E2, with leucine in
386 of 415 sequences, glutamine in 28 of 415 sequences, and
threonine in 1 of 415 sequences. Alignment of other arthritogenic
alphaviruses with CHIKV showed that I190, Y199, G209, and
I217 are conserved, whereas Q184, S185, V197, and L210 are
divergent, particularly in RRV (Figure 3A).
To corroborate the alanine-scanning mapping results, we
introduced amino acid substitutions into CHIKV E2 ectodomain
and generated recombinant proteins in E. coli (Pal et al., 2013)
for binding studies (Figures 4A–4J). Amino acids in CHIKV E2 B
domain were changed to the corresponding amino acids in
RRV (Q184T, S185A, V192A, N193G) to previously defined
escape mutations (G209E, L210P, K215E, K233E) against other
neutralizing mouse MAbs or to residues (R68A and D250A) in the
E2 A domain that showed loss of binding to other human MAbs
(Pal et al., 2013; Smith et al., 2015). Binding of CHK-84, which
maps to the A domain (data not shown), was not altered by
any of the mutations, suggesting that the recombinant proteins
folded correctly (Figure 4D). The majority of the E2 protein resi-
dues identified by alanine-scanning mutagenesis as part of the
epitope (Figure 3A) were confirmed, and additional substitutions
(e.g., Q184T, G209E, and L210P) that disrupted bindingwere de-
tected. Binding of all cross-neutralizing MAbs tested was
affected to varying levels by mutations at Q184, G209, and
L210 (Figures 4A–4J). Mutation at S185 also was associated
with loss of binding of several broadly neutralizing MAbs (Figures
4B, 4C, 4E, 4G, and 4H). These residues all are located within or
immediately adjacent to the cryo-EM-determined footprint of
CHK-265 (see structural analysis in Figure 5D) and thus comprise
an epitope for broadly neutralizing MAbs.
When CHK-48, CHK-65, CHK-77, CHK-88, CHK-124, CHK-
265, and 8I4 were tested for inhibition of RRV infection, they
were poorly (CHK-65, CHK-77, CHK-88, and CHK-124), weakly
(CHK-48 and 8I4), or only moderately (CHK-265) neutralizing
(Figures 1C and 1H). To explore whether virus-specific amino
acid differences in the epitope explained the reduced neutraliza-
tion of RRV, we changed two residues in the E2 protein of the
RRV cDNA clone to the corresponding CHIKV residues (184
[T/Q] and 185 [A/S]). The introduction of the two CHIKV
amino acids into RRV resulted in improved binding and neutral-
ization of RRV byCHK-48, CHK-65, CHK-77, CHK-88, CHK-124,
CHK-187, and CHK-265 (Figures S4 and 4K–4Q). Engineering of
two other CHIKV residues into RRV (192 [A/V] and 193 [G/N])
also improved binding (Figure S4) and neutralization (Figure 4R)
of MAb CHK-98, which mapped to residues 189, 191, 192, and
193 in the B domain (Figure 3A).
Binding of B Domain MAbs Is Coincident with Structural
Rearrangement of CHIKV E2
We determined the structure of CHIKV virions in complex with
Fab fragments of CHK-265 by cryo-electron microscopy (cryo-
EM) at 16 A˚ resolution (Figure 5A). Three Fab molecules were
bound to each of the q3 and i3 trimeric spikes within the 60
icosahedral asymmetric units. Unexpectedly, the virus density
remaining after subtraction of the fitted CHK-265 Fab density
could not be interpreted by fitting of the crystal structure of the
E1-E2 heterodimer (Voss et al., 2010) (Figures S5A and S5B).
Visual inspection suggested that the A and B domains in the
Figure 2. CHK-187 or CHK-265 Protect against Alphavirus Disease and Dissemination In Vivo
(A–D) Four-week-old WT mice were pretreated with 100 mg of CHK-187, CHK-265, or WNV E60 (isotype control) MAb 1 day prior to inoculation with 103 FFU of
(A, B) CHIKV or (C, D) MAYV in the footpad. (A and C) Footpad swelling (width 3 height) in the ipsilateral and/or contralateral joint was measured prior to and
3 days following inoculation (n = 10 to 12). (B and D) Viral load was determined in indicated tissues 3 days following inoculation (n = 6–7).
(E–H) Six- to seven-week-old Ifnar/mice were administered MAbs as described above 1 day prior to inoculation with 10 FFU of ONNV in the footpad. (E) Mice
(n = 8) were monitored for 18 days, and disease was scored as described in the Supplemental Experimental Procedures section. (F) Footpad swelling in the
ipsilateral foot was followed during the course of infection (n = 8). (G) Weight was monitored each day and normalized to starting weight (n = 8). (H) The indicated
tissues were collected 5 days after infection, and viral load was determined (n = 6).
For clinical measurements (panels A, C, F, and G), the mean and SD are shown, with the dashed line indicating the baseline prior to infection. For (A) and (C),
statistical significancewas determined by a one-way ANOVAwith a Bonferroni post hoc test. For (F) and (G), statistical significancewas determined by a two-way
ANOVA with a Bonferroni post hoc test adjusting for repeated measures. For viral titers (B, D, and H), the median value is shown with the limit of sensitivity of the
assay displayed as a dashed line. Statistical significance was determined by a Kruskal-Wallis with a Dunn’s post hoc test. Each graph represents data obtained
from at least two independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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Figure 3. Broadly Neutralizing MAbs Map to Domain B of the E2 Protein
(A) CHIKV, ONNV, SFV, MAYV, and RRV were aligned using MegaAlign (DNA Star) with strain names following the virus. The B domain of CHIKV is highlighted in
yellow. Residues mapped by alanine-scanning mutagenesis (see Figure S3) are in solid colored circles (mouse MAbs) or triangles (human MAbs). Additional
residues identified as critical for MAb binding to the recombinant CHIKV E2 protein (Figure 4) are shown as an ‘‘X’’ in the MAb color.
(B) Mapped residues are shown as spheres on the CHIKV p62-E1 structure using PyMOL (PDB 3N42). Residues identified for a single MAb are indicated with
a colored sphere corresponding to the MAb color in (A). Residues important for binding of multiple MAbs are colored in increasing shades of gray (light gray,
2–3MAbs; medium gray, 4 MAbs; dark gray, 5 MAbs; and black, 7–8MAbs). Residues identified forR4MAbs are indicated on the E2 structure by an arrow. E1 is
shown in yellow and E3 in tan. E2-A is in cyan, E2-B in dark green, and E2-C in purple.
(C) Blow-up of E2 B domain with key residues (R3 MAbs with loss of binding) shown as sticks using Pymol (PDB: 3N42). The percent variation of amino acids in
CHIKV strains is indicated to the right of the residue and was determined by aligning 415 different CHIKV E2 protein sequences.
See also Figure S3.heterodimer had undergone substantial conformational change.
To define this change, the A and B domains were removed from
the crystal structure before fitting the remainder of the modified
E1-E2 dimer, and then the A and B domains were fitted manually
into the density using EMfit to maximize the average densities for
each domain (Rossmann et al., 2001) (Table S3). This process
showed that the position and orientation of the B domain had
moved further over the fusion loop in domain II of E1 protein. In
addition, the A domain had undergone a large repositioning (a
translation of 21 A˚ and rotation of 71) around the domain II of
E1 (Figures 5B and S5C–S5E and Movies S1 and S2). In this1100 Cell 163, 1095–1107, November 19, 2015 ª2015 Elsevier Inc.new position, CHK-265 Fab binds the B domain on one spike
and contacts the A domain on a neighboring spike, effectively
cross-linking the spikes on the virion surface (Figure 5C and
Movie S3); each q3 spike is linked to two neighboring q3 spikes
and one i3 spike, and each i3 spike is linked to three neighboring
q3 spikes. The C termini of the constant domains of Fab mole-
cules that are bound to neighboring spikes make contacts with
each other across quasi 2-fold axes in a manner consistent
with the T4 quasi symmetry surface lattice. This result suggests
that the intact CHK-265 IgG might be able to bind and cross-link
many of the spikes together. The interface between CHK-265
and the virus consists of 19 residues in the B domain and 4 in the
A domain (Figure 5D and Table S4). The cryo-EM-determined
footprint of CHK-265 on the B domain (amino acids 180–220)
is consistent with the identified loss- or gain-of-binding residues
(e.g., Q184, S185, V192, N193, G209, and L210) from the muta-
genesis-based strategies described above.
Broadly Neutralizing MAbs Inhibit Both Viral Entry and
Egress
We evaluated the mechanism of inhibition for two broadly
neutralizing MAbs, CHK-187 and CHK-265. Inhibition of viral
attachment was assessed by pre-incubating CHK-187, CHK-
265, or an isotype control MAb with CHIKV and then adding
the mixture to cells at 4C. CHK-187 and CHK-265 did not block
viral attachment any more strongly than did the isotype control
MAb (Figure 6A). Entry blockade was tested by pre-incubating
CHIKV with CHK-187, CHK-265, or with the isotype control
MAb and then allowing it to bind to cells at 37C. One hour later,
unbound virus and MAb were removed by extensive washing,
and infectivity was assessed 18 hr later. Exposing CHIKV to
CHK-187 and CHK-265 only at the time of entry resulted in
neutralization that was comparable to when MAbs were main-
tained throughout infection, suggesting that entry blockade is a
dominant mode of inhibition (Figure 6B). To determine whether
MAb valency affected entry blockade, studies were repeated
with Fab fragments. The Fab fragments were somewhat less
potent (5- to 10-fold) than their IgG counterparts (Figure 6B).
Saturating amounts of either CHK-187 or CHK-265 Fab frag-
ments could not inhibit infection completely and resulted in a
substantial neutralization-resistant fraction. This result suggests
that, while monovalent binding of B domain MAbs can inhibit the
entry step of infection, bivalent binding is required for complete
neutralization.
Since CHK-187 and CHK-265 blocked at a post-attachment
entry step, we tested whether they inhibited fusogenic activity
using a liposomal fusion assay (Smit et al., 1999). Pyrene-labeled
CHIKVwas incubated withMAbs andmixed with liposomes, and
a low-pH (5.1) buffer was added to trigger fusion. In contrast to
results with potently neutralizing type-specific MAbs that bind
preferentially to the A domain and completely block fusion (Pal
et al., 2013), the cross-neutralizing B domain MAbs showed var-
iable inhibition: fusion was blocked weakly (20%) by CHK-187,
moderately (60%) by CHK-265, and more strongly (80%) by
CHK-88, although none inhibited completely (Figure 6C).
We next evaluated whether B domain MAbs also could block
viral egress, presumably by inhibiting assembly or budding from
the plasma membrane. Cells were inoculated with CHIKV and
then washed extensively to remove free virus. Subsequently,
CHK-187, CHK-265, or isotype control MAb was added, and
viral RNA was analyzed from supernatants harvested at 1 or
6 hr; 6 hr corresponds to the initial round of virion secretion. Addi-
tion of CHK-187 or CHK-265 reduced the amount of CHIKV RNA
in the supernatant compared to cells treated with the isotype
control MAb (Figure 6D). Fab fragments of CHK-187 or CHK-
265 were less potent than intact IgG, suggesting that cross-link-
ing of E2 proteins on the cell or virion surface might contribute to
blockade of egress (Figure 6E). To confirm these results, we
transfected CHIKV RNA directly into cells, then added CHK-C187, CHK-265, or isotype control MAb, and monitored accumu-
lation of RNase-A-resistant encapsidated CHIKV RNA in the
cells and supernatant. CHK-187 and CHK-265 had equivalent
levels of intracellular viral RNA but had reduced accumulation
of viral RNA in the supernatant compared to the isotype control
MAb at 24 hr (Figure 6F). Finally, we determined the relative
contribution of entry and egress blockade to cross-neutralization
of MAYV. CHK-187 or CHK-265 inhibited MAYV infection at the
entry (Figure 6G) and egress (Figure 6H) steps, although the ef-
fects on egress were less than that observed with CHIKV. Taken
together, these results indicate that, while broadly neutralizing
MAbs can inhibit multiple steps (including fusion and egress)
in the alphavirus lifecycle, they preferentially cross-neutralize
infection by blocking entry at a post-attachment pre-fusion step.
DISCUSSION
This study describes a panel of broadly neutralizing MAbs
against multiple and distantly related arthritogenic alphaviruses.
We identified ten mouse and human cross-neutralizing MAbs
and showed that two of these MAbs protected in vivo against
infection with homologous and heterologous alphaviruses. A
conserved epitope in the B domain of the E2 protein contributed
to the recognition of these broadly neutralizing MAbs. Structural
analysis of CHIKV complexed with CHK-265 showed a large
conformational change in the A domain of E2. Mechanistically,
the B domain MAbs blocked CHIKV infection at both viral entry
and egress steps, although the cross-neutralizing activity was
due primarily to inhibition of entry. Collectively, these results
describe a class of broadly neutralizing MAbs with substantive
inhibitory activity against different members of the alphavirus
genus.
We detected a larger number of broadly neutralizing mouse
compared to human MAbs. While this could reflect a sampling
bias of a small number of mice and a single human (Smith
et al., 2015), it could suggest that the epitope repertoire is
different between the species, as has been observed with anti-
bodies against other viruses. In contrast to individuals who
develop broadly neutralizing antibodies to HIV through constant
exposure to the escaping viral envelope protein and extensive
somatic hypermutation over time (Doria-Rose et al., 2014),
sequencing of 8I4, the broadly neutralizing anti-alphavirus hu-
man MAb, revealed no evidence of such selection. Thus, selec-
tion for clones with specific and extensive somatic mutations, as
required for HIV envelope protein antigens (Dosenovic et al.,
2015), may not be required to elicit broadly neutralizing anti-
bodies against alphaviruses.
Although CHK-187 and CHK-265 neutralized infection of
CHIKV and MAYV equivalently in cell culture, greater protection
in mice was observed against MAYV compared to CHIKV. The
phenomenon in which an antibody raised against one virus pro-
tects to greater levels against a related virus was observed pre-
viously with flaviviruses. MAbs recognizing the conserved fusion
loop of WNV E protein provided greater protection against DENV
thanWNV (Oliphant et al., 2006; Williams et al., 2013). In contrast
to CHK-187 and CHK-265, the flavivirus-specific fusion loop-
specific MAbs showed greater neutralizing activity in cell culture
against DENV than WNV. The differences in protection in vivoell 163, 1095–1107, November 19, 2015 ª2015 Elsevier Inc. 1101
(legend on next page)
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between CHIKV and MAYV with the same MAbs having equal
neutralizing activity could reflect differences in tropism, patho-
genesis, or propensity for accumulation of escape mutations
with sustained virulence. Alternatively, the impact of effector
functions (e.g., complement or antibody-dependent cellular
cytotoxicity) on control of the different viruses could vary be-
tween models; these factors could be relevant especially for
MAbs that block egress and bind to E1 or E2 proteins on the sur-
face of infected cells.
Of the arthritogenic alphaviruses tested in this study, RRV had
the greatest divergence in B domain sequence from CHIKV and,
accordingly, was neutralized least efficiently by anti-CHIKV
MAbs. MAbs that localize to the B domain on E2 of RRV have
been reported to have neutralizing activity (Davies et al., 2000;
Vrati et al., 1988), although their capacity for cross-neutralization
was not assessed. Based on loss-of-binding studies with variant
CHIKV E2 proteins, several key residues (Q184, S185, V192,
N193, G209, and L210), all close to or within the cryo-EM deter-
mined footprint of CHK-265, contributed to the binding of
broadly neutralizing anti-alphavirus MAbs. Four of these resi-
dues differed in RRV and, accordingly, substitution of the CHIKV
amino acids at corresponding positions into RRV resulted in
a gain-of-neutralization phenotype. Since RRV and CHIKV
currently do not circulate in the same endemic regions, it seems
unlikely that RRV evolved these changes to evade pre-existing
immunity against CHIKV.
Our findings with B domain MAbs may be relevant in the
context of vaccination, as cross-neutralization of different alpha-
viruses by polyclonal antibodies has been observed. Cross-
protection by anti-RRV serum against CHIKV infection and
anti-CHIKV serum against ONNV infection was reported in
mice (Gardner et al., 2010; Partidos et al., 2012). However, serum
orMAbs derived fromONNV-infected animals or humans weakly
neutralized CHIKV (Blackburn et al., 1995; Porterfield, 1961).
Future genetic analysis paired with reagents that deplete
cross-neutralizing B domain antibodies in serum is needed to
explain fully the basis for the directionality of inhibition of poly-
clonal serum of different alphaviruses.
Cryo-EM structures of several alphaviruses have shown that
the B domain has a lower electron density, implying that its po-
sition varies by roughly 4 A˚ relative to the best average orienta-
tion of the icosahedral symmetry axes (Porta et al., 2014; Sun
et al., 2013). Similarly, the B domain is disordered in the low-
pH crystal structure of CHIKV trimeric spikes (Li et al., 2010)
and has a high ‘‘temperature’’ factor in the crystal structure of
the CHIKV E2-E1 heterodimer (Voss et al., 2010). This structural
feature is important because the fusion loop on domain II of the
E1 protein is hidden under the B domain to prevent adventitious
fusion. Thus, the capacity for the B domain to move likely isFigure 4. Mutation of Domain B Residues Eliminates Binding to CHIKV
(A–J) Mutations were introduced into the CHIKV E2 ectodomain, and binding was
determined by a one-way ANOVA with Dunnett’s multiple comparison tests (*p <
(K–R) Serial dilutions of MAbs were incubated with 102 FFU of RRV-WT, RRV-T18
virus mixture to Vero cells for 18 hr. Cells were fixed, and virally infected foci were
determine the relative infection. EC50 values are shown as ng/ml. Each graph sho
duplicate.
See also Figure S4.
Crequired for the fusogenic activity of the CHIKV. In the cryo-EM
map of CHIKV complexed with CHK-265, the B domain had an
electron density height equal to the other glycoprotein domains
in all four quasi-equivalent positions within the icosahedral
asymmetric unit. This configuration likely occurs because the
Fab fragment bridges the normally flexible B domain to a second
contact site in the more stable A domain. With the B domains
tethered, it is more difficult for the fusion loops in E1 to be
exposed, which might explain the observed partial inhibition of
viral fusion. Another unusual feature of the cryo-EM map is that
domain I of E1 has lower density than the other domains,
implying a greater flexibility. This domain connects domain II to
domain III of E1 that forms the base of the spike. A flexible
domain I might result in a floppy trimeric spike, which could
impair entry functions of the virus.
In a previous study with Fab fragments of four different MAbs
bound to CHIKV-like particles, binding did not cause major
conformational changes to the structure of the virus (Sun
et al., 2013). These antibodies bound primarily to the A
domain of E2. In contrast, CHK-265 Fab binding is centered
in the B domain and is coincident with large conformational
changes. The cryo-EM analysis of the CHK-265-virion complex
showed that although the orientation of the A domain is
changed radically, the putative receptor binding site (Sun
et al., 2013) remains accessible. This finding is consistent
with the observation that CHIKV can attach efficiently to cells
in the presence of CHK-265. Binding of CHK-265 induced a
conformational shift of the four quasi T-4 related A domains
to sites between neighboring spikes, consistent with the
T = 4 quasi-symmetry. Although mutagenesis studies did not
identify residues in the A domain that resulted in loss of binding
of CHK-265, amino acid H73 in domain A of E2 contributed to
the binding of the broadly neutralizing MAb CHK-187. This res-
idue is present in the cryo-EM-determined binding footprint of
CHK-265.
Vaccine- and antibody-based therapy efforts against HIV,
IAV, and DENV have focused on the induction or generation of
neutralizing antibodies that target most strains of a virus within
a given genus. These broadly neutralizing antibodies function
by binding to conserved glycans, receptor-binding domains,
stem regions, or dimer and trimer contacts of the envelope gly-
coproteins (Corti and Lanzavecchia, 2013). Our description of a
class of MAbs that induces marked structural changes in the
virion, inhibits infection at multiple steps in the viral lifecycle,
and protects in vivo against disease pathogenesis by multiple
alphaviruses suggests that targeting of the B domain on E2
could serve as a strategy for the development of vaccines
with utility against CHIKV and several related viruses of global
concern.E2 and Enhances Neutralization of RRV
determined by ELISA. Significant reduction compared to theWT E2 protein was
0.05, **p < 0.01, ***p < 0.001).
4Q/A185S, or RRV-A192V/G193N for 1 hr at 37C followed by addition of MAb-
stained. Wells containing MAb were compared to wells containing no MAb to
ws the mean and SD from two to three independent experiments performed in
ell 163, 1095–1107, November 19, 2015 ª2015 Elsevier Inc. 1103
Figure 5. CHK-265 Binding to CHIKV Results in Repositioning of the E2 A Domain
(A) Cryo-EM reconstruction of CHIKV 181/25 in complex with CHK-265 Fab fragments. The triangle represents one icosahedral asymmetric unit. The colors
indicate the radial distance in A˚ from the center of the virus, as shown on the scale bar.
(B) (Left) Structure of the E1-E2 heterodimer (PDB: 3N42). (Right) Structure of the E1-E2 heterodimer with the bound Fab molecule, as observed in the cryo-EM
complex of the virus with CHK-265. The CHK-265 Fabmolecule is colored blue, and the CHIKV E1-E2 heterodimer (PDB: 3N42) is colored with E1 in gray, E2-A in
cyan, E2-B in green, E2-C in purple, and the E2-b-ribbon in orange. The left and right ribbon structures are oriented to place the lower parts of these figures (E1
and domain E2-C) into the same orientation. The E2 A and E2 B domains are circled, showing the difference in their conformations.
(C) Roadmap showing footprint of CHK-265 Fab projected onto the surface of CHIKV. The projections are colored according to the radial distance of the surface
from the center of the virus, as shown in the scale bar. The white contours are the radial projections of the bound Fab molecules onto the surface of the virus. The
black triangle denotes the boundary of an icosahedral asymmetric unit. The 5-fold, 3-fold, and 2-fold icosahedral axes are indicated by a small black pentagon,
triangle, and oval symbol, respectively. The residues in the Fab footprints are shown in white. Each Fab footprint bridges separate trimers with the variable portion
of the Fab binding to the E2-B domain on one spike and the E2-A domain on a neighboring spike.
(D) Enlargement of a part of the q3 spike shown on the right in (C). The A and B domains of E2 are outlined in yellow. Individual surface amino acids are labeled and
outlined in black. To differentiate residues in E1 from those in E2, a value of 500 arbitrarily was added to the E1 residue numbers. The roadmaps were created by
the program RIVEM (Xiao and Rossmann, 2007).
See also Figure S5, Table S3 and S4, and Movies S1, S2, and S3.
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Figure 6. Broadly Neutralizing Anti-CHIKV MAbs Block Steps in Viral Entry and Egress
(A–F) Mechanism of action studies with CHIKV. (A) Attachment blockade. CHIKV was incubated with CHK-187, CHK-265, or isotype control MAb (Iso; WNV E60)
for 1 hr, added to chilled Vero cells for 1 hr at 4C, and washed extensively, and bound CHIKV viral RNA was measured. RNA levels are normalized to a no
MAb treatment control. (B) Entry blockade. 102 FFU of CHIKV were incubated with indicated MAbs or Fabs at 37C for 1 hr, added to Vero cells for 1 hr at 37C,
washed extensively, overlaid with methylcellulose, and fixed 18 hr later. Wells containing MAb were compared to wells containing no MAb to determine the
relative infection. (C) Fusion blockade. Pyrene-labeled CHIKV was incubated with 1.5 mg/ml of the indicated MAbs and mixed with liposomes at 37C, and fusion
was triggered with a low-pH (5.1) buffer. The percent fusion was measured over time compared to a no MAb control. (D–F) Egress blockade. Vero cells were
inoculated with (D, E) CHIKV for 2 hr at 37C and rinsed extensively, and medium containing (D, E) IgG or (E) Fab fragments (10 mg/ml) and 25 mM NH4Cl was
added back. Supernatant was collected 1 or 6 hr later, the latter of which corresponds to the first round of virion production, and was analyzed for CHIKV viral
RNA. (F) BHK21 cells were transfected with CHIKV RNA and rinsed extensively, and medium containing 10 mg/ml IgG and 25 mM NH4Cl was added. Cells and
supernatants were collected 1 or 24 hr later, treated with RNase A at 37C to degrade unencapsidated RNA, and analyzed for CHIKV viral RNA. See Figure S6 for
additional controls.
(G and H) Mechanism of action studies with MAYV. (G). Entry blockade. Studies were performed as described above in (B) using 102 FFU of MAYV. (H) Egress
blockade. Studies were performed as described above in (D) using MAYV at an MOI of 1 and analyzed for MAYV viral RNA.
Graphs in this figure show the mean and SD of two or three independent experiments performed in triplicate or duplicate. EC50 values for entry blockade are
shown as ng/ml and were determined by non-linear regression. Statistical significance for the egress blockade assay was determined using a one-way ANOVA
with a Bonferroni post hoc test at each MAb concentration and time point (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).EXPERIMENTAL PROCEDURES
Antibodies, Cell Culture, and Viruses
Mouse and human MAbs against CHIKV were reported previously (Pal et al.,
2013; Smith et al., 2015) and were purified by Protein A Sepharose and S200
size-exclusionchromatography.PurifiedCHK-265andCHK-187weredigested
with papain (Pierce) to generate Fab fragments and were collected in the flow-
through after passage over a Protein A Sepharose column. Vero, BHK21, and
C6/36 cells were cultured as described (Pal et al., 2013). CHIKV (La Reunion
OPY1 p142) and RRV (T48) were the gifts of S. Higgs (Kansas State University)
and R. Kuhn (Purdue University), respectively, and were produced from infec-
tious cDNA clones (Morrison et al., 2006; Tsetsarkin et al., 2006). MAYVC(BeH407), ONNV (MP30), SFV (Kumba), BEBV (MM 2354), MIDV (30037),
GETV (AMM-2021), UNAV (CoAr2380), and BFV (K10521) were provided by
the World Reference Center for Arboviruses and propagated in Vero cells.
Focus Reduction Neutralization Assay
Focus reduction neutralization tests (FRNT) were performed as described (Pal
et al., 2013). Additional details are reported in the Supplemental Experimental
Procedures.
Mouse Studies
Experiments were carried out in accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes ofell 163, 1095–1107, November 19, 2015 ª2015 Elsevier Inc. 1105
Health after approval by the Institutional Animal Care and Use Committee at
the Washington University School of Medicine. MAbs CHK-187 or CHK-265
or isotype control MAb WNV E60 (100 mg in PBS, 6 mg/kg) were administered
to 4-week-old WT C57BL/6 mice or 6- to 7-week old Ifnar/mice by intraper-
itoneal injection 1 day prior to infection. WT mice were infected subcutane-
ously in the footpad with CHIKV or MAYV. Ifnar/ mice were inoculated in
the footpad with ONNV. Animals were scored daily using a modified clinical
disease scale created for RRV (Morrison et al., 2006). Additional information
is in the Supplemental Experimental Procedures.
Mutagenesis of CHIKV E2 and ELISA
Amino acid substitutions were introduced into the CHIKV E2 ectodomain (res-
idues S1-E361) using Quikchange II mutagenesis (Aligent) and the primers
listed in Table S1. Mutations were confirmed by direct sequencing of plasmid
DNA. MAb binding to CHIKV WT or mutant E2 proteins was assessed by
ELISA. Detailed protocols are described in the Supplemental Experimental
Procedures.
Mutagenesis of RRV Infectious Clone
A double mutation at positions 192(A/V) and 193(G/N) of the E2 gene was
introduced into the pRR64 cDNA clone of RRV by Quikchange II mutagenesis
(Aligent). Double mutations at positions 184(T/Q) and 185(A/S) of the E2
gene were engineered using Phusion high-fidelity DNA polymerase (New
England BioLabs). The mutagenesis primers are listed in Table S1. Mutations
were confirmed by sequencing with separate primers (Table S2). WT and
mutant RRV were produced after plasmid linearization, in vitro transcription,
and electroporation into BHK21 cells. Additional details of RRV mutagenesis
are provided in the Supplemental Experimental Procedures.
Cryo-EM Reconstruction of CHK-265 in Complex with CHIKV
Purified CHK-265 Fab molecules (5 mg/ml) were mixed with purified and
concentrated CHIKV (181/25) in 2:1 (Fab:E2) molar ratio and incubated on
ice for 30 min. Samples were flash frozen on holey carbon grids (Ted Pella)
in liquid ethane using Cryo-plunge 3 (CP3) in a biosafety cabinet. CCD im-
ages of the CHIKV-Fab complex were recorded under low-dose conditions
(22 e/A˚2) using a FEI Titan Krios electron microscope operated at 300 kV
and 47,0003 magnification. All cryo-EM images were collected at about
1.5–3 mm below the focus level. A total of 5,828 particles was selected
manually with the e2boxer program in the EMAN2 suite (Kimoto et al.,
2003; Tang et al., 2007). Contrast levels of micrographs were corrected using
the ctfit program in EMAN (Ludtke et al., 1999; Tang et al., 2007). Additional
information about the purification of CHIKV and CHK-265 Fabs and the
cryo-EM model generation is described in the Supplemental Experimental
Procedures.
Mechanistic Analyses of MAb Inhibition
(a) For virus attachment inhibition assays, MAbs were incubated with CHIKV
at 37C, chilled, and added to pre-cooled Vero cells. Cells were extensively
rinsed, and bound RNA was extracted from the cells and measured by
qRT-PCR. (b) For entry inhibition assays, MAbs or Fabs were incubated
with virus at 37C, added to Vero cells, and after extensive rinsing, processed
as described for the FRNT assay. (c) Liposomal fusion inhibition assays were
performed as described (Pal et al., 2013). (d) For egress inhibition assays,
Vero and BHK21 cells were infected with virus or transfected with viral
RNA, respectively. Cells were rinsed extensively, and MAbs or Fabs were
added in medium containing NH4Cl. Viral RNA was quantified from superna-
tant or cells. Detailed protocols are described in the Supplemental Experi-
mental Procedures.
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